Loading clinical trials...
Loading clinical trials...
A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2
Conditions
Interventions
herceptin
adriamycin
+2 more
Locations
149
United States
Comprehensive Cancer Institute
Huntsville, Alabama, United States
Providence Alaska Medical Center
Anchorage, Alaska, United States
CCOP - Western Regional, Arizona
Phoenix, Arizona, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Sutter Health Western Division Cancer Research Group
Greenbrae, California, United States
Scripps Cancer Center at Scripps Clinic
La Jolla, California, United States
Start Date
February 1, 2000
Primary Completion Date
March 1, 2005
Completion Date
November 1, 2019
Last Updated
April 29, 2021
NCT05468034
NCT04541381
NCT03137095
NCT07547774
NCT06393374
NCT07040891
Lead Sponsor
NSABP Foundation Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions